|
Number of patients |
471 |
|
Length of hospital stay: days, median (IQR) |
16 (9 – 26) |
|
Length of ICU stay: days, median (IQR) |
9 (5 – 16) |
M |
In-hospital mortality: n (%) |
128 (27.2%) |
B |
Burst Suppression Burden: median % (IQR) |
9% (0% – 60%) |
D |
Propofol: mg/kg, median (IQR) |
230.5 (86.7 – 570.4) |
Patient covariates including critical illness (C) |
Age: year, median (IQR) |
61 (50 – 72) |
Gender: n (%) |
Female 233 (49.5%); Male 238 (50.5%) |
Smoker: n (%) |
225 (47.8%) |
Alcohol: n (%) |
125 (26.5%) |
Substance abuse: n (%) |
57 (12.1%) |
APACHE II: median (IQR) |
23 (20 – 27) |
CCI: median (IQR) |
3 (1 – 6) |
Initial Glasgow Coma Scale score: median (IQR) |
7 (3 – 13) |
Premorbid modified Rankin Score: median (IQR) |
0 (0 – 2) |
Structural brain injury: n (%) |
295 (62.6%) |
Hypertension: n (%) |
252 (53.5%) |
Respiratory failure: n (%) |
182 (38.6%) |
Seizures / status epilepticus on presentation: n (%) |
106 (22.5%) |
Hemorrhagic stroke: n (%) |
94 (20.0%) |
Cardiovascular accident: n (%) |
92 (19.5%) |
Subarachnoid hemorrhage: n (%) |
83 (17.6%) |
Septic shock: n (%) |
76 (16.1%) |
Toxic metabolic encephalopathy: n (%) |
74 (15.7%) |
History of seizure: n (%) |
72 (15.3%) |
Subdural hematoma: n (%) |
49 (10.4%) |
CNS infection or inflammation: n (%) |
48 (10.2%) |
Ischemic stroke: n (%) |
40 (8.5%) |
Cardiac failure: n (%) |
39 (8.3%) |
Renal failure: n (%) |
35 (7.4%) |
Brain tumor: n (%) |
30 (6.4%) |
Brain Surgery: n (%) |
29 (6.2%) |
Malignancy solid tumors hematologic: n (%) |
27 (5.7%) |
Liver failure: n (%) |
24 (5.1%) |
Primary psychiatric disorder: n (%) |
20 (4.2%) |
CNS Cancer: n (%) |
15 (3.2%) |
Endocrine emergency: n (%) |
10 (2.1%) |
Primary hematological disorder: n (%) |
9 (1.9%) |
Systemic hemorrhage: n (%) |
3 (0.64%) |